Give Online: Help shape patient care for generations to come.
Cleveland Clinic Florida Logo



Request an Appointment



Contact us with Questions

International: + 001 954.659.5080

Expand Content

Cancer Research

Cleveland Clinic Florida's Cancer Research staff is dedicated to providing patients innovative therapies through clinical research trials which include new targeted agents and therapies. Cancer specialists from The Maroone Cancer's Departments of Hematology and Oncology serve as principal investigators for the trials, working closely with the research staff and collaborating with the world-renowned Taussig Cancer Institute at Cleveland Clinic in Ohio. Cleveland Clinic Florida also participates in many clinical trials with the National Cancer Institute.

For more information about our clinical trials, please contact:
Abel Rodriguez, Clinical Research Supervisor
Phone: 954.487.2258

Reviewed: 09/15

Areas of Cancer Clinical Trials

Breast Cancer

PUMA1113: A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)

A Phase 2 Double-Blinded, Randomized, Placebo- Controlled Study of Indoximod in Combination with a Taxane Chemotherapy in Metastatic Breast Cancer

Molecular Mechanisms Involved in Cancer Predisposition

  • Cleveland Clinic Study Number: IRB 8458
  • Principal Investigator: Charis Eng, MD / Asheley Supik, MS, CGC
Colon Cancer

SWOG S1406 - Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant Folfox Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer


A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer


GS-US-352-1214 - A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib

A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

Lung Cancer

TIGER-1 - A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation

Adjuvant Lung Cancer Enrichment Market Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512

Randomized Double Blind Placebo Controlled Study of ERLOTINIB or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

A Phase III Double-Blind Trial for Surgically Resected Early State Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Prostate Cancer

A Randomized Phase III Study Of Neo-Adjuvant Docetaxel And Androgen Deprivation Prior To Radical Prostatectomy Versus Immediate Radical Prostatectomy In Patients With High-Risk, Clinically Localized Prostate Cancer

Androgen Deprivation Therapy And High Dose Radiotherapy With Or Without Whole-Pelvic Radiotherapy In Unfavorable Intermediate Or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial